Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Toyota Global Sales Fall as China Demand Slumps 
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Street Poller Media and The Boom of the Street Interview Ad Industry 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Amazon Secures 200 MW Wind Power Deals in Sweden 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Add as a preferred source on Google
DURHAM, N.C., April 02, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett Nichols, M.D., M.S., Chief Medical Officer of Chimerix will present at the H.C. Wainwright Annual Global Life Sciences Conference on Monday, April 9, 2018 at 10:15 a.m. CET at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
